ZIOPHARM ONCOLOGY INC (45) | Intellectual Property (4)
Browse by Subcategory
Recent Contracts
-
Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute
(Filed With SEC on November 5, 2020)
-
Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020
(Filed With SEC on November 5, 2020)
-
Amendment to Patent License Agreement, dated as of January 8, 2020 , by and between the Company and the National Cancer Institute
(Filed With SEC on March 2, 2020)
-
Patent License Agreement, dated as of May 28, 2019, by and between the Company and the National Cancer Institute
(Filed With SEC on August 8, 2019)
